Form 15-12G PEGASUS TEL, INC.

 

 

 

 

  

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 

 

 

 

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION

12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE

REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 0-5268

 

Pegasus Tel, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Bloemendallseweg 69, 2061 CC

Bloemendallseweg, Netherlands 2061

Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

	Rule 12g-4(a)(1)	☐
	Rule 12g-4(a)(2)	☒
	Rule 12h-3(b)(1)(i)	☐
	Rule 12h-3(b)(1)(ii)	☐
	Rule 15d-6	☐
	Rule 15d-22(b)	☐

 

 

 

 

 

Approximate number of holders of record as of the certification or notice date: 494

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Water Pure International Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: April 29, 2026	By:	/s/ Lorenzo Luciano Piceni
		Name: Lorenzo Luciano Piceni. CEO

 

 

 

 

 

 

Instruction: This form is required by Rules 12g-4, 12h-3, 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
• FLSmidth: Transactions under share buy-back programme
• Vantiva: Amendment and Extension of Credit Facilities